If Drake's reps are appointed to the board it won't matter what...

First 75 Last

Share
Profile

Follow
InItEarly

3,200 Posts.

1038

27/10/22

18:40

Post #: 64439442
Share

Originally posted by longreach: ↑

So lets be very clear Patong. If elected Andrew Roberto will be declaring ALL Drake shareholdings as a Related Shareholding? Is that correct? I'm not referring to any direct shareholdings of Andrew Roberto, I'm referring specifically to the Drake holdings currently declared, which form part of a portfolio that presumably Andrew Roberto, as an employee of Drake must be considered as a Related Party shareholding.

(It appears you have been given the approval to speak on behalf of Drake, as at least on one occasion previously you have stated "we" when referring to a comment that would otherwise be necessarily left for Drake to respond to.)

Wrt your remark:
"The vast majority of the decrease in ownership stake is through dilution from capital raises". Just to emphasise, Drake sold a NET 1.5 million shares. In such a low traded stock it was very significant, and its no wonder there has been considerable manipulation of the share price. I wonder if this has been brought to the attention of the regulator. If you actually Hold a lot of shares Patong, surely you would not be defending Drake on this point.

Go on Patong, do the work, rather than the flippant observation: "Lastly, Mclarty was a substantial holder as he had 6mm shares at a time when there were far fewer shares outstanding." WAS he a Substantial holder or not, and did any sales transaction of his drop his equity either down 1% from a declaration of being a Substantial shareholder or below the 5% threshold? If you can prove that, then I agree with you.

"Because of a miscalculation, Drakes back office didn’t realize they had gone over 1%, and it was immediately rectified when realized."
"Immediately rectified" - really. Over a period of how many months do you consider "immediately". Even then they failed to declare it correctly, they needed a few attempts, and it was still unclear. And you want them checking on SMN books? That is hysterical.

Expand

If Drake's reps are appointed to the board it won't matter what we think of Drake anymore.

SMN Price at posting: 43.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 2 more messages in this thread...

First 75 Last

Add SMN (ASX) to my watchlist

(20min delay)
Last 57.5¢		Change 0.025(4.55%)		Mkt cap ! $78.98M

Open	High	Low	Value	Volume
57.5¢	57.5¢	57.5¢	$1.438K	2.5K

Buyers (Bids)

No.	Vol.	Price($)
1	4518	55.0¢

Sellers (Offers)

Price($)	Vol.	No.
61.0¢	1000	1

View Market Depth

No.	Vol.	Price($)
1	4518	0.550
1	12500	0.540
1	4644	0.535
2	12500	0.530
1	10000	0.525

Price($)	Vol.	No.
0.610	1000	1
0.625	9109	1
0.630	6837	1
0.670	1500	1
0.690	6000	1

Last trade - 15.52pm 07/10/2024 (20 minute delay)

SMN (ASX) Chart

If Drake's reps are appointed to the board it won't matter what...

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

If Drake's reps are appointed to the board it won't matter what...

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News